Plenary II
This session will review the latest science in the field of head and neck cancer.
Target Audience
This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Describe the latest science in the field of head and neck cancer.
Alexander Pearson, MD, PhD, is employed by the University of Chicago and receives research grants from NIH/NIDCR, NIH/NCI, American Cancer Center, Cancer Research Institute, Adenoid Cystic Carcinoma Research Foundation, SU2C, Kura Oncology, Abbvie,is on the advisory board of Prelude Therapeutics, Elevar Therapeutics and Ayala and has stock ownership in Doximity.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.